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This year’s Annual Review Issue of The Journal of Pathology contains 18 invited reviews on 
current research areas in pathology. The subject areas reflect the broad range of topics 
covered by the journal and this year encompass the development and application of software 
in digital histopathology; implementation of biomarkers in pathology practice; genetics and 
epigenetics; and stromal influences in disease. The reviews are authored by experts in their 
field and provide comprehensive updates in the chosen areas, in which there has been 
considerable recent progress in our understanding of disease.  
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This is the 22nd consecutive year that The Journal of Pathology has published an Annual 
Review Issue. As with all previous Issues, the manuscripts contained herein are freely 
available online (see https://onlinelibrary.wiley.com/journal/10969896). This 2020 Annual 
Review Issue covers a diverse range of subject areas in which we feel there has been 
considerable recent progress. Given the aims of the Journal to act as a translational bridge 
between basic biomedical science and clinical medicine, the subjects relate to recent 
advances in basic research that aid understanding of disease processes, as well as reviews 
of specific areas of more immediate clinical relevance. We hope that these articles will be of 
use equally for pathologists and scientists across the world. 
 
Recent advances in epigenetics and non-coding RNAs in health and disease 
The first article in this section discusses the current thinking on long non-coding RNAs 
(lncRNAs) and their roles in development and disease. Julie Aspden and colleagues firstly 
provide a definition for lncRNAs and discuss the different categories of lncRNAs that have 
been identified. The conservation of lncRNAs and its value for inferring function are critically 
reviewed, followed by a discussion of the potential functions of lncRNAs according to their 
intracellular location. The review concludes with a comprehensive analysis of the evidence 
that some lncRNAs play important roles in normal development, in neurodegenerative 
disease and in human malignancies, suggesting their potential as biomarkers and/or 
therapeutic targets. Strikingly, although there are more than 16,000 lncRNAs in our genome, 
only about 50 of these are understood at a functional level [1]. Our second review in this area 
deals with the recent data on microRNAs (miRNAs) in multiple sclerosis (MS), indicating that 
each type of MS lesion in the white and grey matter shows a distinct miRNA profile. The 
functional effects of these different miRNAs are discussed, paying particular attention to the 
cell types involved and the possibility of exosomal delivery of miRNAs. In addition, certain 
miRNAs are shared, whilst other miRNAs show opposite regulation in different lesions. Since 
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miRNAs can be detected in blood or cerebrospinal fluid (CSF), they may act as biomarkers 
for disease. Thus, the investigation of miRNAs has inspired novel concepts for the 
pathogenesis and pathophysiology of MS, with potential diagnostic and monitoring 
applications [2]. The third review in this area examines DNA methylation in disease, 
concentrating on stratification of brain tumours for appropriate treatments matched to the 
underlying biology of the tumour. The review covers the role of molecular profiling, 
highlighting that DNA methylation has had the largest impact of these approaches for brain 
tumour classification. The authors also assess how machine learning-based algorithms are 
being developed and applied for clinical application in these diseases. This field can be 
regarded as an example of how molecular profiling influences the understanding of disease 
processes, as well as providing unanticipated benefits for pathology practice, along with 
certain risks [3]. 
 
Genetics of cancer 
This Annual Review Issue contains three reviews that deal with very different aspects of 
cancer genetics. The first of these reviews current understanding of the molecular genetic 
causes of Lynch syndrome and the emergence of associated tumours. In particular, the 
authors discuss the methods and their interpretation involved in accurate diagnosis, together 
with providing sources of appropriate databases and current information on this subject. 
These approaches include genetic analysis, but also the application of immunohistochemical 
approaches based on the underlying defects [4]. The second review provides an update on 
the role of capicua (CIC) in human malignancies. Recurrent mutations in the CIC gene were 
first identified in oligodendroglioma, but CIC is now known to be dysregulated in multiple 
tumour types including sarcomas, adenocarcinomas of stomach, lung and breast, melanoma 
and multiple myeloma, mainly through translocation, point mutation or homozygous or 
heterozygous deletion. The review discusses the role of CIC in normal neurogenesis and 
development of other organs and the effects of its dysregulation in malignant diseases, 
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where it is now clear that CIC acts as a tumour suppressor and its loss associates with poor 
clinical features. The new and emerging information on this previously poorly studied gene 
suggests multiple actions, including cell cycle regulation, metabolism, genome stability and 
epigenetic regulation that contribute to its normal functions and to its effects in malignancy 
[5]. The final contribution in this section discusses how Mendelian randomisation can be 
used to identify causal links between an exposure and a specific outcome. In this approach, 
genetic variants are used as a proxy for exposure and are subsequently analysed for 
outcome in the population with the variant; this can be considered as a “natural” randomised 
clinical trial. As such, Mendelian randomisation can theoretically identify new risk factors as 
well as serving to validate or refute current views. The review from Harvinder Gala and Ian 
Tomlinson discusses the history, basic principles and methodologies of Mendelian 
randomisation approaches, together with the current limitations and potential improvements. 
The article concludes with examples of how Mendelian randomisation has been employed in 
studies of cancer and in identifying cancer predisposition traits [6]. 
 
Stromal cells and cancer microenvironments  
The effects of tumour microenvironments have perhaps been neglected in the recent past 
due to the emphasis placed on the identification of gene mutations in the tumour cells 
themselves and their roles in promoting growth, survival, etc. However, pathologists have 
long known that tumours are heterogeneous and that the non-malignant cells admixed with 
the tumour are important determinants of malignancies and their progression. In particular, 
Sabine Galland and Ivan Stamenkovic discuss the current views on mesenchymal stromal 
cells (MSCs, also referred to as mesenchymal stem cells), which represent a key population 
of pluripotent cells involved in normal organogenesis and tissue homeostasis, regeneration 
and repair, as well as tumour formation and progression. Due to their currently loose 
definition, MSCs probably exist as several subpopulations with diverse functional properties.  
In cancer, MSCs may directly promote or inhibit growth and progression through cell-cell 
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contact interactions or secreted factors, or indirectly through modifying innate and adaptive 
immune responses. This review provides a detailed summary of MSC subtypes and their 
regulation and dysregulation in normal situations and in tumour growth and suppression, 
including the potential role of MSC-derived exosomes and MSCs as targets for therapeutic 
intervention. Remaining issues in this field include the identification and definition of MSC 
subtypes, the differences between MSCs and other or more differentiated stromal cells, and 
their respective contributions to disease [7]. Macrophages are a second cell type increasingly 
recognised as playing important roles in tumour pathology. Tumour-associated macrophages 
(TAMs) have been intensively investigated in the past decade for their phenotypes and their 
functions, reviewed here by Tim Beltraminelli and Michele De Palma [8]. In addition to 
summarising the recent advances in our knowledge of TAMs and their functions in promoting 
angiogenesis, suppressing anti-tumour immunity, facilitating metastasis and imparting drug 
resistance, the authors highlight the results of recent pre-clinical trials and the clinical 
development of novel therapies that target TAMs [8]. The third review article in this section 
comes from Christopher Pugh and colleagues, who provide an updated view of tumour 
hypoxia, concentrating on the roles of diagnostic pathology and tissue-based research rather 
than cell culture based research. Their article discusses how mammalian cells sense oxygen 
(including a recently recognised system originally identified in plants) and how gradients of 
oxygen availability produce microenvironments in cancers. The concept of pseudohypoxia is 
introduced, where oncogenic stimulation produces constitutive activation of hypoxia 
responses, which has direct relevance for tumour evaluation. The article also includes an 
overview of the different methodologies available to quantify tumour hypoxia and recent 
approaches to targeting hypoxia-related pathways that depend on knowledge of the 
signalling components being utilised by the individual tumour [9]. Finally in this section, we 
include a review of the effects of tumour environments in driving plasticity of cell migration 
programmes that lead to metastatic spread. Savvas Nikolaou and Laura Machesky discuss 
the two major mechanisms of cancer cell invasion, achieved by single or by collective cell 
invasion pathways. In the former, migration of individual cells is controlled by the Rho 
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GTPase Rac1, interacting with the Scar/WAVE complex and causing nucleation of branched 
actin filaments that enables the formation of lamellipodia, filopodia and invadopodia. 
Collective cell adhesion additionally requires coordination of cell-cell adhesion and/or 
repulsion and involves the activities of both leader cells and follower cells that show 
differences in morphology, gene expression and signalling pathway activation. The review 
discusses these processes in terms of the stressful environment in which tumour cells exist. 
The data indicate that both normal and tumour cells adapt migration and invasion according 
to the various stresses and demands of their environment and that a better understanding of 
the range of responses may reveal weaknesses that can be exploited therapeutically [10].  
 
Inflammation, damage and repair  
Chronic obstructive pulmonary disease (COPD) is caused by exposure to damaging particles 
and gases. Current treatments aim to improve symptoms and prevent exacerbations, but 
there are no treatments that modify the disease itself, nor are there any that are based on the 
individual’s pathology. Wim Timens and colleagues review the recent progress in defining 
and understanding the underlying processes that are responsible for abnormal inflammatory 
responses and extracellular matrix changes that lead to altered small airways in this disease, 
including gender-associated features and the effects of age. The improved ability for disease 
endotyping and the ensuing development of strategies using biological agents to target 
specific pathological features will allow personalised treatments in the future [11]. M. 
tuberculosis, the causative agent of tuberculosis, has evolved multiple strategies to persist 
within infected cells and hijack immune mechanisms, leading to tissue damage in the host. 
Persistence also inhibits the effects of antibiotic therapies and allows the development of 
drug-resistant strains. These factors have led to the development of a radically different 
approach to therapy, the targeting of host immune responses rather than targeting of the 
infectious agent. This host-directed therapy (HDT) approach can enhance the effect of 
antibiotics to shorten treatment times, promote immunological memory to protect against 
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relapse, and reduce the pathology associated with long-term immune response including 
matrix destruction and fibrosis. Liana Tsenova and Amit Singhal review the pathology of 
tuberculosis including the heterogeneity of pathologies caused by infection and the host 
reactions that are induced. They emphasise recent data on HDT with already available drugs 
such as metformin, statins, corticosteroids, imatinib, inhibitors of phosphodiesterase or 
indolamine dioxygenase, and the gastric proton-pump inhibitor, lansoprazole. They conclude 
that HDT is a promising line of approach, tailored to the individual’s lesions and their immune 
status [12].  
The third review in this section comes from Bill McBride and Dörthe Schaue on the damaging 
effects of ionising radiation and the subsequent tissue responses. They introduce the 
historical aspects of radiation effects that have guided radiation oncologists and review 
recent data using, for example, cell lineage tracing to investigate heterogeneity of effects 
according to cell and tissue types. This structural diversity and plasticity within tissue 
compartments is the major theme of the review. In general, tissues with rapid turnover and 
highly proliferative stem/progenitor cells show acute responses, whereas slow turnover 
tissues show late responses and rely more on proliferation and re-programming events in 
mature cells. In addition, they highlight that inflammation may play an important role in 
causing tissue failure, as well as potentially enhancing anti-cancer immune responses for 
immunotherapy. The authors conclude that recent advances in radiotherapy may change our 
views, including that hypofractionation may have adverse effects on rapid turnover tissues 
and inflammatory responses, whilst the introduction of charged particles such as protons and 
carbon ions provides uncertainties particularly for late responding tissues [13]. Finally in this 
section, Siamon Gordon and colleagues review the key roles that macrophages play in 
coordinating the response to a wide variety of insults, as well as their roles in maintaining 
tissue homeostasis and development. Macrophages are heterogeneous cell populations and 
display a wide variety of surface receptor molecules that bind and respond to host and 
exogenous ligands including pathogenic organisms. These receptor-ligand interactions are 
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the main theme of the review, including a detailed discussion of the receptor molecules and 
their roles in recognising and removing pathogens and effete and dying host cells. The 
presence of these surface molecules provides information about macrophage function and 
phenotypes and the review argues that their use as antigen markers has lagged in clinical 
pathology, as has their potential as drug targets in immunotherapy [14].  
 
Modern approaches and new technologies in research and clinical practice 
Immunotherapy is an increasingly attractive therapy for a variety of cancer patients. The 
most common approach is immune checkpoint inhibition based on PD-L1, which is now a 
standard of care for several haematological and solid tumour types in many countries. The 
assessment of PD-L1 is therefore a key biomarker for patient selection. The whole area of 
immune checkpoint inhibition is reviewed by a worldwide set of experts, coming from a total 
of 79 groups of clinical and scientific researchers, led by Paula Gonzalez-Ericsson and 
Melinda Sanders. The authors review current practice relating to PD-L1 assessment in triple 
negative breast cancer using the different antibodies and systems available, including 
variability between platforms and inter-reader reproducibility. They emphasise that PD-L1 is 
only one component of the immunological spectrum, leading to the proposal that tumour-
infiltrating lymphocytes (TILs) should also be assessed. They therefore suggest a 
standardised approach combining immunohistochemistry for PD-L1 with TIL assessment in 
haematoxylin and eosin-stained sections as an improved biomarker for PD-1/PDL-1 inhibition 
therapy. The path to implementation in clinical trials and daily practice through a risk 
management framework is also presented. Although the review is specifically related to triple 
negative breast cancer, the approach has obvious value for other solid tumour types [15]. On 
a related theme, the accurate and reproducible quantification of target molecules is a 
prerequisite for the type of study in the previous review. This area is rapidly advancing in 
pathology research and is reviewed by Ralf Huss and Sarah Coupland, who discuss the 
application of multiplex staining methods, high resolution imaging and image analysis tools to 
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aid tissue diagnostics and research. They discuss that, together with high end computer 
hardware, machine- and deep-learning solutions, there is a huge opportunity to improve the 
potential of personalised medicine to enable the administration of modern and emerging 
therapeutics. They emphasise especially that these digitalised and computerised approaches 
and the resulting software-driven clinical decision-making process will require significant 
changes in education and training for their introduction into clinical routines [16]. 
The final two articles in the 2020 Annual Review Issue concern the use of newly developed 
single cell methodologies and their impact on understanding both normal physiology and the 
pathophysiology of selected conditions. Single cell methodologies have increased massively 
in scale and scope, including the ability to perform genome-wide RNA or DNA sequencing in 
individual cells. The epigenetic landscape of single cells can also be identified, as can sites 
of active gene transcription. Such methodologies have a vast number of potential 
applications. Benjamin Stewart and Menna Clatworthy review single cell technologies in 
general, and focus on the new information provided in renal diseases. For example, they 
point out that single cell transcriptional profiling has identified the specific cell types affected 
by renal disease susceptibility genes, indicating that many nephrotic syndrome genes are 
expressed by podocytes, genes associated with hypertension are expressed in nephron 
tubular cells, and lupus susceptibility genes are expressed in B-cells infiltrating the kidney in 
lupus nephritis. In particular they review how these technologies will bridge the gap between 
molecular characterisation and classic morphological approaches to nephropathology [17]. 
The other review on the use of single cell technologies comes from Lisa Willemsen and 
Menno PJ de Winther on the subject of immune cells in atherosclerotic plaques. In their 
review they provide a detailed consideration of how single cell methodologies, including 
CyTOF (cytometry by time of flight; which allows high dimensional protein analysis of single 
cells) and single cell RNAseq approaches, have combined to define three main macrophage 
subsets in atherosclerotic plaques. These three subtypes, resident-like, pro-inflammatory and 
anti-inflammatory TREM2hi foamy macrophages show specific locations in the plaque and 
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have specific phenotypes and functional properties. Their review also discusses some of the 
limitations of current single cell studies, including high technical noise and variability of single 
cell RNAseq data with false-negative read counts, which are being improved by analytical as 
well as methodological advances [18].  
 
Conclusion 
This collection of invited review articles illustrates the pace of change in the technology that 
can be applied to research focused on understanding disease mechanisms, and also shows 
how such research can have a rapid impact on disease diagnosis and patient management. 
We hope that these reviews will be of value to the readership of the Journal. 
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